Charles Schwab Investment Management Inc. Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Charles Schwab Investment Management Inc. increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 1.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 293,700 shares of the company’s stock after acquiring an additional 3,691 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Tarsus Pharmaceuticals were worth $16,262,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth about $4,291,000. Jennison Associates LLC lifted its position in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after acquiring an additional 698,712 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter worth approximately $282,000. FMR LLC increased its position in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Ally Bridge Group NY LLC purchased a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at $10,587,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TARS shares. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Barclays dropped their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $63.67.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $330,093.99. Following the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. This represents a 9.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,542 shares of company stock valued at $1,281,173 over the last 90 days. 8.25% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Trading Up 0.7 %

TARS opened at $49.91 on Friday. The business’s 50 day moving average price is $48.54 and its 200 day moving average price is $45.06. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.